Investment Thesis

.

Competitive Moat

characterized by its intangible assets, particularly its extensive intellectual property portfolio and established brand reputation in the biopharmaceutical sector. The company benefits from high switching costs associated with its therapies, especially in chronic conditions like asthma and macular degeneration, where patients are unlikely to transition to alternative treatments. This advantage is reinforced by regulatory barriers that protect its key products from competition for several years. However, competitive threats from emerging biopharma firms and the potential for biosimilars to disrupt market share in established treatments pose challenges that must be monitored.

Growth Engine

Future revenue growth for Regeneron will predominantly stem from its continued dominance in the ophthalmology and immunology markets, targeting an estimated total addressable market (TAM) that exceeds $40 billion. The company's flagship products, EYLEA and Dupixent, are expected to see expanded indications and increased penetration in both existing and new markets. Additionally, ongoing development of new therapies in oncology and rare diseases will further diversify its revenue streams. Regeneron is gaining market share, driven by its innovative product pipeline and a strong sales force focused on educating healthcare providers.